52 results about "Colon cancer tumor" patented technology

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.

The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.

The invention belongs to the field of tumor gene therapy, and specifically relates to a recombinant mouse mIL-22BP vector and preparation methods and application of a liposome complex thereof. The invention, in view of the problem that a liposome complex having the murine IL-22BP gene has not been reported so far, provides the recombinant murine IL-22BP vector and the liposome complex thereof. Thevector contains a gene encoding mouse IL-22BP protein and can be used for expressing mouse IL-22BP protein in eukaryotic cells; after vector is combined with a cationic liposome to form the complex,the complex can well play a role of resisting colon cancer tumor tissue growth, has a tumor growth resisting effect, can be used for preparing drugs for diagnosis or treatment of tumors, and providesa new choice for tumor treatment.

Disclosed are novel compositions, methods and vaccines, which upon administration to a patient suffering from a melanoma, colon carcinoma tumor or breast cancer, postpone and/or reduce the need for chemotherapy treatment, slow the progression of or eliminate the tumor and/or alleviate the symptoms of the tumor. The compositions comprise stressed colon carcinoma, melanoma or breast cancer cells, preferably autologous such cells.

The invention discloses a quantum dot targeting probe kit for detecting the tumor of colon cancer. The kit comprises (a) TCP-1-H6 polypeptide, (b) TP-1-H6 polypeptide, (c) water soluble quantum dots, (d) FITC, and (e) DAPI. Water soluble quantum dots and targeting TCP-1-H6 polypeptide are coupled through His-tag and taken as a fluorescence probe (TCP-1-H6-QD). TCP-1-H6-QD can specifically label the acceptor of colon 26 cell and tumor tissue slice of colon cancer, and will not recognize normal colon tissues and brain tissues. The provided kit has an important meaning for the diagnosis and treatment of color cancer.

The invention relates to an application of rhizopus nigricans exopolysaccharides in preparation of a medicine for treating or preventing gastrointestinal tumors. The method for preparing the rhizopus nigricans exopolysaccharides comprises the following steps: (1) activating and performing fermental cultivation on rhizopus nigricans with a strain collection number of CGMCC NO.8436, and preparing fermentation liquor; (2) separating and purifying the fermentation liquor, and preparing a crude extracting solution; and (3) discoloring the crude extracting solution by resin columns, oscillating to remove proteins through a Seveage reagent, performing column chromatography purification on Sephadex G-50 sephadex, and preparing the rhizopus nigricans exopolysaccharides. An animal tumor model is established by utilizing the rhizopus nigricans exopolysaccharides, the tumor activity of an entity anti-alimentary system of the rhizopus nigricans exopolysaccharides is explored, the animal tumor experiment anti-tumor result proves that the rhizopus nigricans exopolysaccharides can obviously inhibit growth of tumor blocks of stomach cancer tumor mice and colon cancer tumor mice, and when the rhizopus nigricans exopolysaccharides are combined with modern chemotherapy drug cyclophosphamide, the anti-tumor curative effect is obviously higher than the anti-tumor effect of a single cyclophosphamide drug.

The invention discloses an application of a humanized antibody for resisting 4-1BB. The antibody can be used for detecting 4-1BB, blocking a 4-1BB/4-1BBL signal channel, stimulating T cell activation, promoting T cell secretion of IFN-gamma, inhibiting colon cancer tumor and cell growth, and treating and/or preventing colon cancer. The HCDR1, the HCDR2 and the HCDR3 of the antibody are sequentially shown as the 31st site to the 35th site, the 50th site to the 64th site and the 98th site to the 106th site of SEQ ID No.1, and the LCDR1, the LCDR2 and the LHCDR3 are sequentially shown as the 24th site to the 34th site, the 50th site to the 56th site and the 89th site to the 97th site of SEQ ID No.2. The antibody provided by the invention has high affinity to human 4-1BB, can effectively enhance T cell response, can be used for regulating T cell and antibody mediated immune response, and can be used as an immunomodulator for treating cancers, autoimmune diseases, inflammatory diseases, infectious diseases and the like.

The invention discloses the application of a 4-1H-1,2,3-triazole-beta-lactam derivative. The 4-1H-1,2,3-triazole-beta-lactam derivative is used for preparing a medicine for resisting human brain glioma and colon cancer. The 4-1H-1,2,3-triazole-beta-lactam derivative has better biological activity, and is proved to have stronger propagation inhibitory activity for the human brain glioma (U87mG) and colon cancer tumor (LS-174T) cells by in vitro activity test. Therefore, the 4-1H-1,2,3-triazole-beta-lactam derivative is a potential antitumor drug, and has the application of preparing antitumor pharmaceutical preparation.

The invention discloses application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of a chemotherapeutic drug combined with the trichoderma pseudokoningii exopolysaccharide in treating the colon cancer. The trichoderma pseudokoningii exopolysaccharide (EPS) can significantly inhibit the growth of tumor masses in a mouse with the colon cancer, and can improve mouse immune organ index and the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum, increase the proportion of mouse cytotoxic T lymphocytes (CD8+T cells) in total T lymphocyte calculation and significantly activate mouse T lymphocytes and B lymphocytes; therefore, the EPS has an effect on treating the colon cancer; and the EPS, when taken for a preventive purpose, can also effectively improve the antitumor capacity of a body. In addition, the EPS, when combined with an existing chemotherapeutic drug, namely 5-fluorouracil (5-FU), is significantly better than the single medication of the 5-FU in antitumor effect. Moreover, the EPS can improve the life quality of the mouse with the colon cancer and can prolong the service life of the mouse.

The invention relates to the technical field of biology, and discloses the applications of human RRS1 gene in screening tumor treatment drugs and preparing tumor diagnosis/treatment drugs and an inhibitor. The human RRS1 gene is taken as the target, a proper target gene sequence is selected, and then an inhibitor is designed through a RNA interference mode, the inhibitor can efficiently inhibit the expression of RRS1 gene, and inhibit the nucleic acid molecules, recombinant carriers, slow viruses, which can promote the proliferation of human tumor cells especially colon cancer cells; the invention further provides applications of human RRS1 gene in screening tumor treatment drugs and preparing tumor diagnosis/treatment drugs, and the means for treating tumors are increased.

The present invention discloses the use of a Cistanche deserticola polysaccharide in the preparation of functional food having efficacy of supplementary for inhibiting colon cancer, wherein Cistanche deserticola polysaccharide is preferably prepared by the following method: with Cistanche deserticola as raw material, is prepared by the processes including extraction with boiling water, deproteinization, dialysis and ethanol treatment, the Cistanche deserticola polysaccharide has an effect of regulating tumor microenvironment, the Cistanche deserticola polysaccharide according to the present invention is able to regulate tumor microenvironment by many pathways of inhibiting tumor angiogenesis, immunosuppression, anti-oxidation and inhibiting the growth of colon cancer fibroblast etc., which demonstrate that it has good effect of supplementary for inhibiting colon cancer tumor.

The invention discloses an application of polysaccharide of cistanche deserticola to preparation of functional foods with effects of assistance in inhibiting colon cancer. Polysaccharide of cistanche deserticola is preferably prepared by adopting a preparation method comprising the following steps: with cistanche deserticola as a raw material, extracting with boiling water, and performing deproteinization, dialysis and ethanol treatment. Polysaccharide of cistanche deserticola has a function of regulating a tumor microenvironment. Polysaccharide of cistanche deserticola provided by the invention is capable of regulating the tumor microenvironment through multiple approaches of inhibiting tumor angiogenesis, suppressing the immunity, resisting oxidation and inhibiting the colon cancer fibroblast growth, and the like so as to indicate that polysaccharide of cistanche deserticola has a good function of assistance in inhibiting the colon cancer.

The invention relates to application of aspirin in preventing or treating colon cancer and also relates to a medicinal composition containing the aspirin. The aspirin can relieve the decrease degree of platelet activation rate and inhibit the migration ability and invasion ability of tumor cells. The invention studies a biological regulation mechanism of the aspirin for the tumor microenvironmentof colon cancer and the medicinal effect on the colon cancer and provides a new idea for deep research and development of the aspirin and clinical treatment of the colon cancer.

Compounds and compositions are provided which inhibit MIF. Methods of treatment of melanoma and colon cancers are also provided.